XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million

XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs

Read more at globenewswire.com